Cloud-Clone expands autoimmune disease research toolkit

Cloud-Clone Corp. says it has built an end-to-end research portfolio for systemic autoimmune diseases, spanning recombinant proteins, antibodies, primary cells and animal models. The company says the platform is designed to help researchers study disease heterogeneity, validate targets and speed preclinical drug development.

Why it matters: - Systemic autoimmune diseases remain hard to study and treat because disease biology varies widely across patients and organs. - Cloud-Clone is positioning its reagents, cell models and animal models as a single workflow for researchers trying to move from basic mechanism studies to drug translation. - The company says the platform is meant to reduce experimental variability and support faster target discovery and pharmacodynamic testing.

What happened: - Cloud-Clone Corp. unveiled an integrated toolkit for autoimmune-disease research covering molecular reagents, primary-cell models and in-vivo disease models. - The portfolio is aimed at systemic autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, type 1 diabetes, psoriasis and experimental autoimmune encephalomyelitis. - The release was issued Nov. 3, 2026, from Houston.

The details: - The molecular reagent lineup includes recombinant proteins and target-specific antibodies for anti-SSA/Ro, anti-SSB/La antibodies, inflammatory cytokines and cell-specific markers. - Cloud-Clone says those reagents have been validated on Western Blot, IHC and ELISA platforms. - The company says the antibodies and proteins support autoantibody screening, inflammatory-pathway profiling, immune-cell phenotyping and key-protein measurement. - Cloud-Clone’s animal-model library includes induced models and spontaneous genetic models. - For rheumatoid arthritis, the company offers collagen-induced arthritis and adjuvant-induced arthritis models. - The collagen-induced arthritis model is described as producing joint synovitis, synovial proliferation, cartilage and bone destruction, paw swelling and joint deformity. - The adjuvant-induced arthritis model is described as having a short modeling cycle and stable phenotypes. - For systemic lupus erythematosus, Cloud-Clone offers the MRL/lpr spontaneous lupus mouse model. - The MRL/lpr model carries an lpr gene mutation that impairs Fas-protein function and lymphocyte apoptosis, and it develops autoantibodies, glomerulonephritis, vasculitis, splenomegaly and lymphadenopathy. - For type 1 diabetes, the company offers an STZ-induced model described as straightforward to operate, lower cost and rapid in onset. - Cloud-Clone also says it can provide custom models for psoriasis and EAE. - The company says all animal-model services include standardized workflows and data sets covering body weight, clinical scores, serum autoantibodies, cytokines and H&E histopathology. - Cloud-Clone says its primary-cell library includes more than 540 products across human, mouse, rat, rabbit, dog and other species. - The cell portfolio includes keratinocytes, dermal fibroblasts, synoviocytes, chondrocytes, vascular endothelial cells, microglia and macrophages.

Between the lines: - The release is as much about platform breadth as single products. - Cloud-Clone is trying to address the same bottleneck at multiple stages: molecular discovery, cell-based validation and animal testing. - The company is leaning into heterogeneity as the core pain point in autoimmune research, which makes standardization a central selling point.

What's next: - Cloud-Clone says it will continue optimizing its full-chain research-tool portfolio. - The company is targeting researchers working on biomarker discovery, target validation and preclinical evaluation of autoimmune-disease therapies. - The broader goal is to support faster translation of basic autoimmune findings into drug development.